What MEDIRA does

MEDIRA GmbH is a privately held, development-stage medical technology company headquartered in Balingen in the Swabian Alb region of southern Germany, operating within the Medical Valley medtech cluster. The company designs, develops, and manufactures transcatheter cardiovascular implants for the treatment of structural heart disease, with the explicit goal of becoming a globally recognized technology leader among cardiac specialists. Its current portfolio comprises three proprietary device platforms: TRICENTO (and the second-generation TRICENTO G2), a heterotopic transcatheter valve system for severe symptomatic tricuspid valve insufficiency implanted via transfemoral-venous access and anchored in the inferior and superior vena cava; ACORA, a transapical transcatheter repair system for symptomatic mitral valve insufficiency that closes the coaptation gap using an integrated biological valve; and BREVA, an Endo-Bentall concept combining an endovascular stent graft with a catheter-based aortic valve prosthesis for the treatment of acute Type A aortic dissection. The company also operates MEDIRA Aortic as a dedicated sub-brand for aortic treatment solutions.

MEDIRA has not yet commercialized any of its products. Its go-to-market model is built around direct engagement with tertiary and quaternary cardiac care centers and physician training, supported by clinical collaboration and a planned regulatory pathway. Future revenue is expected to be generated through hardware sales of medical devices to hospitals and cardiac centers following CE marking and other regulatory approvals. The integrated Balingen facility houses development laboratories, testing capabilities, clean rooms, and complete in-house manufacturing under one roof, providing high manufacturing depth for a company of its stage. The leadership team is almost entirely composed of former JOTEC GmbH and CryoLife Inc. executives, led by co-founder and Managing Director Thomas J. Bogenschütz, the former CEO of JOTEC and SVP/GM at CryoLife. MEDIRA is privately held (GmbH, registered at Amtsgericht Stuttgart, HRB 772661), with no public listing, no disclosed funding rounds, and no reported revenue.

Name

MEDIRA

Legal name

MEDIRA GmbH

Website

https://medira.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

MEDIRA GmbH is a development-stage German medical technology company designing transcatheter cardiovascular implants (TRICENTO, ACORA, BREVA) for structural heart disease, serving cardiac specialists and tertiary heart centers once its products receive regulatory approval.

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

akta.pro secondary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Transcatheter valve systems
• Structural heart devices
• Cardiovascular implants
• Mitral valve repair
• Tricuspid regurgitation treatment

Headquarters

HQ city

Balingen

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Cardiovascular Medical Devices: MEDIRA develops cardiovascular implants for structural heart disease treatment. Products are in development phase (TRICENTO, ACORA, BREVA) and not yet commercially available. Revenue will be generated through sale of medical devices to hospitals and cardiac centers following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

MEDIRA develops, manufactures, and intends to market transcatheter cardiovascular implants for the interventional treatment of structural heart disease. The portfolio includes the TRICENTO/TRICENTO G2 transcatheter valve system for tricuspid regurgitation, the ACORA transcatheter repair system for mitral regurgitation, and the BREVA transcatheter system (Endo-Bentall concept) for acute Type A aortic dissection. All three products are currently in development and not yet commercially available; once approved, they will be sold as implants to hospitals and cardiac centers.

Product overview

MEDIRA is a medical technology company developing transcatheter-based cardiovascular implants for the treatment of structural heart diseases. The product portfolio includes TRICENTO/TRICENTO G2 (transcatheter valve systems for tricuspid regurgitation), ACORA (transcatheter repair system for mitral regurgitation), and BREVA (transcatheter system for acute Type A aortic dissection). All products are in development phase and not yet commercially available. The company also operates MEDIRA Aortic as a dedicated sub-brand for aortic treatments. MEDIRA maintains high manufacturing depth with in-house development labs, testing facilities, clean rooms, and complete production under one roof in Balingen, Germany.

Differentiator

Problem solved

Functional benefit

Brands

• TRICENTO: Transcatheter valve system for tricuspid regurgitation - interventionell therapy approach for patients with severe symptomatic tricuspid valve insufficiency
• TRICENTOG2
• ACORA
• BREVA
• MEDIRA Aortic

Products and services

• TRICENTO Transcatheter valve system for treating tricuspid regurgitation. A heterotopic treatment concept that implants an additional valve without touching the native tricuspid apparatus, using a stent-graft-like implant with a lateral bicuspid valve element delivered via transfemoral-venous access and anchored in the inferior and superior vena cava. Targeted at patients with severe symptomatic tricuspid valve insufficiency.
• TRICENTO G2 Second-generation transcatheter valve system for severe tricuspid regurgitation. An evolution of the TRICENTO concept with an improved implant design featuring a lateral bicuspid valve element anchored in the inferior and superior vena cava.
• ACORA Transcatheter repair system for mitral regurgitation. A hybrid approach where the implant closes the coaptation gap of the insufficient mitral valve and restores function through an integrated biological valve, delivered via transapical catheter access and anchored at the apex. Targeted at patients with symptomatic mitral valve insufficiency.
• BREVA Transcatheter system for acute Type A aortic dissection. An 'Endo-Bentall' concept combining an endovascular stent graft with a catheter-based aortic valve prosthesis, delivered transapically to seal the primary intimal tear and stabilize the aortic root. Targeted at patients with acute Type A aortic dissection.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Medical ValleycoreStrategic or Co-development PartnerMEDIRA is integrated into the Medical Valley competence network, a significant medical technology cluster in southern Germany. This strategic partnership provides access to the broader medical technology ecosystem, talent pool, and collaborative innovation opportunities within the cluster.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• CroiValve: Early-stage company developing a transcatheter tricuspid coaptation device. Comparable to MEDIRA's TRICENTO as another niche player targeting the underserved tricuspid regurgitation market.
• 4C Medical Technologies: Developer of transcatheter mitral and tricuspid therapies. Directly comparable to MEDIRA's ACORA (mitral) and TRICENTO (tricuspid) programs as an early-stage structural-heart pure-play.
• JenaValve Technology: Transcatheter aortic valve developer focused on aortic regurgitation and TAVR. Comparable to MEDIRA as a focused structural-heart implant company pursuing differentiated transcatheter valve indications.
• Cardiac Dimensions: Developer of the Carillon transcatheter mitral annuloplasty system and tricuspid program. Comparable to MEDIRA's transcatheter mitral and tricuspid repair focus.

Broad incumbents

• LivaNova: Diversified cardiac surgery and neuromodulation medtech with structural-heart heritage (previous employer of MEDIRA's Head of Development). Comparable as a broad incumbent that competes in structural-heart device categories adjacent to MEDIRA.
• Biotronik: Cardiovascular medical device company (vascular intervention, CRM, structural heart) where MEDIRA's Head of Development previously led prosthesis development. Comparable as a broad incumbent in cardiovascular implants with structural-heart overlap.
• CryoLife / JOTEC: CryoLife acquired JOTEC GmbH (the previous company of MEDIRA's Managing Director and several senior team members). Comparable as both an incumbent structural-heart/surgical graft company and the most direct corporate ancestor of MEDIRA's leadership team.

Direct peers

• Medtronic: Diversified medtech with established transcatheter aortic and emerging structural-heart portfolios. Directly competes in transcatheter valve replacement/repair markets relevant to MEDIRA's pipeline.
• Edwards Lifesciences: Global leader in transcatheter aortic and structural heart valve therapies (TAVR/SAVR/TEER). Directly comparable to MEDIRA as the dominant incumbent in transcatheter valve replacement and repair that MEDIRA's TRICENTO, ACORA, and BREVA programs aim to enter.
• Abbott: Major structural-heart player offering MitraClip for mitral regurgitation and transcatheter tricuspid programs. Closely comparable to MEDIRA across mitral (ACORA) and tricuspid (TRICENTO) indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/medira

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEDIRA